← Eichor
Condition: Relapsed Acute Myelogenous Leukemia Synced from ClinicalTrials.gov · July 30, 2026

Recruiting studies: Relapsed Acute Myelogenous Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Phase 1/Phase 2 · 1 location(s) · Zhujiang Hospital · NCT05270200Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HS
Phase N/A · 1 location(s) · Ciceri Fabio · NCT05124288A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
NA · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT07500753Novel Digital Application for Patients With Acute Leukemia
NA · 3 location(s) · Massachusetts General Hospital · NCT06472128Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute
Phase 1 · 10 location(s) · St. Jude Children's Research Hospital · NCT06177067Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Phase 2 · 1 location(s) · Beijing 302 Hospital · NCT06741722Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06839456Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and
Phase 1/Phase 2 · 26 location(s) · Sellas Life Sciences Group · NCT04588922A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06763341Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · University Hospital, Antwerp · NCT05506332Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling,
Phase N/A · 28 location(s) · Assistance Publique - Hôpitaux de Paris · NCT05772559Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated
Phase 1 · 23 location(s) · Lomond Therapeutics Holdings, Inc. · NCT06366789Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06816134CAV Regimen for R/R AML
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT05657639A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Partici
Phase 1 · 8 location(s) · AbbVie · NCT07306832Niclosamide in Pediatric Patients With Relapsed and Refractory AML
Phase 1 · 1 location(s) · Stanford University · NCT05188170Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Phase 2 · 37 location(s) · Ryvu Therapeutics SA · NCT06191263Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dend
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06006403AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/Phase 2 · 10 location(s) · AB Science · NCT05211570Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 45 location(s) · Kura Oncology, Inc. · NCT06001788Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07584889Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
Phase 1 · 2 location(s) · Montefiore Medical Center · NCT05986240First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
Phase 1 · 3 location(s) · Aspera Biomedicines, Inc. · NCT07250646CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT06696846Imetelstat Combinations in Relapsed AML
Phase 1 · 1 location(s) · Douglas Tremblay · NCT07320235CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT05672147Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic
Phase 1/Phase 2 · 2 location(s) · Gyala Therapeutics · NCT07471789
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.